Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective

AIDS

Volumn 27, Issue 14, 2013, Pages 2281-2290

  Vriend, Henrike J ^a,b   Lugnér, Anna K ^a   Xiridou, Maria ^a   Van Der Loeff, Maarten F Schim ^b,c   Prins, Maria ^b,c   De Vries, Henry J C ^a,b,c   Geerlings, Suzanne E ^b   Prins, Jan M ^b   Rijnders, Bart J A ^d   Van Veen, Maaike G ^a,c   Fennema, Johannes S A ^c   Postma, Maarten J ^e   Van Der Sande, Marianne A B ^a,f  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chlamydia screening; Chlamydia trachomatis; Cost effectiveness; HIV prevention; MSM

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT;

ADULT; AGED; ARTICLE; BACTERIAL TRANSMISSION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONSULTATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; EPIDIDYMITIS; HEALTH CARE COST; HEALTH CENTER; HELP SEEKING BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE FACILITIES; CHLAMYDIA INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HOMOSEXUALITY, MALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; SEXUALLY TRANSMITTED DISEASES; YOUNG ADULT;

EID: 84884469235     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32836281ee     Document Type: Article

References (41)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS; 2010.
2. Wilson DP, Zhang L. Characteristics of HIV epidemics driven by men who have sex with men and people who inject drugs. Curr Opin HIV AIDS 2011; 6:94-101.
3. Patel P, Bush T, Mayer K, Milam J, Richardson J, Hammer J, et al. Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in care. Sex Transm Dis 2012; 39:470-474.
4. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr 2010; 53:537-543.
5. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17:455-480.
6. Levine WC, Pope V, Bhoomkar A, Tambe P, Lewis JS, Zaidi AA, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998; 177:167-174.
7. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579-597.
8. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
9. Workowski KA, Berman S; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59 (RR-12): 1-110; See: http://www.ncbi.nlm.nih.gov/pubmed/21160459.
10. Heiligenberg M, Rijnders B, Schim van der Loeff MF, de Vries HJ, van der Meijden WI, Geerlings SE, et al. High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. Sex Transm Dis 2012; 39:8-15.
11. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010; 39:1048-1063.
12. DeGruttola V, Seage GR 3rd, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989; 42:849-856.
13. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311.
14. Althaus CL, Turner KM, Schmid BV, Heijne JC, Kretzschmar M, Low N. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. J R Soc Interface 2012; 9:136-146.
15. Kretzschmar M, Welte R, van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. Am J Epidemiol 2001; 153:90-101.
16. Regan DG, Wilson DP, Hocking JS. Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis 2008; 198:349-358.
17. Turner KM, Adams EJ, Gay N, Ghani AC, Mercer C, Edmunds WJ. Developing a realistic sexual network model of chlamydia transmission in Britain. Theor Biol Med Model 2006; 3:3.
18. Jin F, Prestage GP, Imrie J, Kippax SC, Donovan B, Templeton DJ, et al. Anal sexually transmitted infections and risk of HIV infection in homosexual men. J Acquir Immune Defic Syndr 2010; 53:144-149.
19. Sadiq ST, Taylor S, Kaye S, Bennett J, Johnstone R, Byrne P, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16:219-225.
20. Berman SM, Cohen MS. STD treatment: how can it improve HIV prevention in the South? Sex Transm Dis 2006; 33:S50-57.
21. Rotchford K, Strum AW, Wilkinson D. Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis 2000; 27:243-248.
22. Stolte IG. In: Dijkshoorn H, van Dijk TK, Janssen AP, editors. Final report Amsterdam Health Monitor 2008 Amsterdam, the Netherlands: Public Health Service of Amsterdam; 2009. pp. 121-125.
23. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Prins M, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22:1071-1077.
24. Gras L, van Sighem A, Smit C, Schuitemaker H, de Wolf F. Monitoring Report 2011. Human immunodeficiency virus (HIV) infection in the Netherlands. Amsterdam, the Netherlands: Stichting HIV Monitoring; 2007.
25. RIVM Evaluation Team. Chlamydia screening implementation Netherlands: Impact evaluation and cost effectiveness. Bilthoven, the Netherlands: National Institute for Public Health and the Environment (RIVM); 2010.
26. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decisionmaking. Washington: Institute of Medicine; 2000.
27. Golden MR, Schillinger JA, Markowitz L, St Louis ME. Duration of untreated genital infections with chlamydia trachomatis: a review of the literature. Sex Transm Dis 2000; 27:329-337.
28. van den Brule AJC, Munk C, Winther JF, Kjaer SK, Jørgensen HO, Meijer CJLM, et al. Prevalence and persistence of asymptomatic Chlamydia trachomatis infections in urine specimens from Danish male military recruits. Int J STD AIDS 2002; 13:19-22.
29. van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metr 2006; 4:14.
30. Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS 2011; 25:1779-1787.
31. Randolph AG, Washington AE. Screening for Chlamydia trachomatis in adolescent males: a cost-based decision analysis. Am J Public Health 1990; 80:545-550.
32. van Sighem A, Smit C, Gras L, Holman R, Stolte I, Prins M, et al. Monitoring Report 2011. Human immunodeficiency virus (HIV) infection in the Netherlands. Amsterdam, the Netherlands: Stichting HIV Monitoring; 2011.
33. Hakkaart-van Roijen L, Durch SS, Bouwmans CAM. Guideline for costing research, methods and standardized priced for economic evaluations in healthcare. Diemen, the Netherlands: Healthcare Insurance Board (CVZ); 2010.
34. Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Jager HC, Coutinho RA. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis. Value Health 2001; 4:266-275.
35. Foundation for Healthcare Insurance. Monitoring Report 2011. Guidelines for pharmacoeconomic research, updated version. Diemen, The Netherlands: Healthcare Insurance Board (CVZ); 2006:; http://www.cvz.nl/binaries/content/ documents/cvzinternet/en/documents/procedures/guidelines-pharmacoeconomic- research.pdf. [Accessed on 15 October 2012].
36. Veen M, Heijman R, Gö tz H, de Wolf F, Zaheri S, Fennema J, et al. Delay of entry into care in HIV positive individuals. Amsterdam, the Netherlands: NCHIV; 2011.
37. van Empelen P, van Berkel M, Roos E, Zuilhof W. Schorer Monitor 2011. Amsterdam, the Netherlands: Schorer; 2011.
38. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Fraser C. 27 years of the HIV epidemic amongst men having sex with men in the Netherlands: an in depth mathematical model-based analysis. Epidemics 2010; 2:66-79.
39. Kelley CF, Haaland RE, Patel P, Evans-Strickfaden T, Farshy C, Hanson D, et al. HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. J Infect Dis 2011; 204:761-767.
40. Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr 2000; 24:48-56.
41. Farley TA, Cohen DA, Wu SY, Besch CL. The value of screening for sexually transmitted diseases in an HIV clinic. J Acquir Immune Defic Syndr 2003; 33:642-648.